Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O5S |
Molecular Weight | 365.404 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O
InChI
InChIKey=LSQZJLSUYDQPKJ-NJBDSQKTSA-N
InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12461003 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
|||
Curative | AMOXIL Approved UseAMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. Launch Date3.40934394E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/836010/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Disc. AE: Pharyngolaryngeal pain... Other AEs: Nausea, Pharyngotonsillitis... AEs leading to discontinuation/dose reduction: Pharyngolaryngeal pain (severe, 0.6%) Other AEs:Nausea (1.5%) Sources: Pharyngotonsillitis (0.9%) Vulvovaginal candidiasis (0.9%) Headache (0.7%) Diarrhea (0.5%) Abdominal pain (0.5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 0.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Diarrhea | 0.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Headache | 0.7% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Pharyngotonsillitis | 0.9% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Vulvovaginal candidiasis | 0.9% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Nausea | 1.5% | 775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
Pharyngolaryngeal pain | severe, 0.6% Disc. AE |
775 mg 1 times / day steady, oral Dose: 775 mg, 1 times / day Route: oral Route: steady Dose: 775 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 302 Health Status: unhealthy Condition: pharyngitis secondary to Streptococcus pyogenes Age Group: > 12 years Population Size: 302 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Acute myocardial infarction after anaphylactic reaction to amoxicillin]. | 1999 Aug |
|
[Amoxicillin caused aseptic meningoencephalitis]. | 1999 Jan 20 |
|
Acute interstitial nephritis following amoxicillin overdose. | 1999 Jun |
|
Aseptic meningitis after treatment with amoxicillin. | 1999 Jun 5 |
|
[Cerebral and renal toxicity of acyclovir in a patient treated for meningoencephalitis]. | 1999 Nov |
|
[Acute renal failure after amoxicillin crystallization]. | 2000 Apr 8 |
|
[Intrahepatic cholestasis induced by amoxicillin alone]. | 2000 May |
|
Adverse reaction to amoxicillin: a case report. | 2000 Sep-Oct |
|
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? | 2001 Apr |
|
A prospective observational study of 5-, 7-, and 10-day antibiotic treatment for acute otitis media. | 2001 Apr |
|
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue. | 2001 Apr |
|
Helicobacter eradication versus prompt endoscopy for dyspepsia. | 2001 Apr |
|
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. | 2001 Apr |
|
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | 2001 Apr 1 |
|
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. | 2001 Apr 6 |
|
Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media. | 2001 Feb |
|
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis. | 2001 Feb |
|
The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins. | 2001 Feb |
|
Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic. | 2001 Feb |
|
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 Feb |
|
[Selection of antibiotics and planning of eradication for H. pylori infection]. | 2001 Feb |
|
Free radical production by antibiotic-killed bacteria in the guinea pig middle ear. | 2001 Feb |
|
Acute generalized exanthematous pustulosis induced by amoxycillin with clavulanate. | 2001 Feb |
|
Topical antibiotic prophylaxis for bacteremia after dental extractions. | 2001 Feb |
|
Definite streptococcus bovis endocarditis: characteristics in 20 patients. | 2001 Jan |
|
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?]. | 2001 Jan |
|
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
A prospective study of antibiotic use and associated infections in young children. | 2001 Jan |
|
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations]. | 2001 Jan |
|
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. | 2001 Jan |
|
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. | 2001 Jan |
|
Neonatal group B streptococcal infection. Results of 33 months of universal maternal screening and antibioprophylaxis. | 2001 Jan |
|
Cause of high variability in drug dissolution testing and its impact on setting tolerances. | 2001 Jan |
|
Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk. | 2001 Jan-Feb |
|
[A prospective study on erysipelas and infectious cellulitis: how are they dealt within hospital?]. | 2001 Mar |
|
Peptic ulcer occurrence in follow-up of chronic gastritis in patients with treated and not eradicated CagA-positive Helicobacter pylori infection. | 2001 Mar |
|
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. | 2001 Mar |
|
Lacrimal gland ductal cyst abscess. | 2001 Mar |
|
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test. | 2001 Mar |
|
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. | 2001 Mar |
|
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 Mar |
|
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 Mar |
|
Evaluation of the clinical microbiology profile of moxifloxacin. | 2001 Mar 15 |
|
[Angina tonsillaris in children. Penicillin V can not be recommended here]. | 2001 Mar 22 |
|
Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. | 2001 Mar 31 |
|
Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. | 2001 Mar 31 |
|
Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae. | 2001 Mar-Apr |
|
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. | 2001 May |
|
Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms by LC with amperometric detection. | 2001 May |
|
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
Sample Use Guides
In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175497
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
||
|
WHO-ATC |
J01CA04
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01060
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
26787-78-0
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
277174
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
DTXSID3037044
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
CHEMBL1082
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
9EM05410Q9
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
9EM05410Q9
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
2676
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
3230
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
3204
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
SUB05481MIG
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
C87367
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
33613
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
M1844
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | Merck Index | ||
|
1297882
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000091596
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY | |||
|
248-003-8
Created by
admin on Wed Jul 05 23:03:48 UTC 2023 , Edited by admin on Wed Jul 05 23:03:48 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)